Aileron Therapeutics Inc
Aileron Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that ha… Read more
Aileron Therapeutics Inc (ALRN) - Total Assets
Latest total assets as of September 2024: $104.22 Million USD
Based on the latest financial reports, Aileron Therapeutics Inc (ALRN) holds total assets worth $104.22 Million USD as of September 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Aileron Therapeutics Inc - Total Assets Trend (2014–2023)
This chart illustrates how Aileron Therapeutics Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Aileron Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2023)
Aileron Therapeutics Inc's total assets of $104.22 Million consist of 17.2% current assets and 82.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 16.3% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $79.20 Million | 74.7% |
| Goodwill | $6.33 Million | 6.0% |
Asset Composition Trend (2014–2023)
This chart illustrates how Aileron Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Aileron Therapeutics Inc's current assets represent 17.2% of total assets in 2023, a decrease from 96.4% in 2014.
- Cash Position: Cash and equivalents constituted 16.3% of total assets in 2023, down from 35.0% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 79.0% of total assets, an increase from 0.0% in 2014.
- Asset Diversification: The largest asset category is intangible assets at 74.7% of total assets.
Aileron Therapeutics Inc Competitors by Total Assets
Key competitors of Aileron Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Aileron Therapeutics Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Aileron Therapeutics Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Aileron Therapeutics Inc is currently not profitable relative to its asset base.
Aileron Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.30 | 7.88 | 3.35 |
| Quick Ratio | 3.30 | 7.88 | 3.35 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $13.03 Million | $ 11.17 Million | $ 13.71 Million |
Aileron Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Aileron Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.88 |
| Latest Market Cap to Assets Ratio | 0.39 |
| Asset Growth Rate (YoY) | 381.7% |
| Total Assets | $106.01 Million |
| Market Capitalization | $40.98 Million USD |
Valuation Analysis
Below Book Valuation: The market values Aileron Therapeutics Inc's assets below their book value (0.39 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Aileron Therapeutics Inc's assets grew by 381.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Aileron Therapeutics Inc (2014–2023)
The table below shows the annual total assets of Aileron Therapeutics Inc from 2014 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | $106.01 Million | +381.70% |
| 2022-12-31 | $22.01 Million | -54.61% |
| 2021-12-31 | $48.48 Million | +196.68% |
| 2020-12-31 | $16.34 Million | -38.27% |
| 2019-12-31 | $26.47 Million | -12.66% |
| 2018-12-31 | $30.31 Million | -42.47% |
| 2017-12-31 | $52.69 Million | +139.26% |
| 2016-12-31 | $22.02 Million | +270.72% |
| 2015-12-31 | $5.94 Million | -66.49% |
| 2014-12-31 | $17.73 Million | -- |